Skip to main content
Login | Suomeksi | På svenska | In English

Browsing by Subject "strategia"

Sort by: Order: Results:

  • Näyttöön pohjautuva poliittinen päätöksenteko ja Lääkepolitiikka 2020 : strategiset painoalat sidosryhmien näkökulmasta 
    Halonen, Henna (2013)
    In Finland pharmaceutical policy is a part of health policy. It concerns social decision making on pharmaceutical sector and people and organizations around pharmaceuticals. Pharmaceutical policy 2020 strategy was prepared by the Ministry of Social Affairs and Health, based on a stakeholder (administrative authorities, education and research, industry, medicine wholesalers, patients, pharmacies, professional organizations, public sector) analysis. In Finnish politics this is an assignment of a new kind of evidence-informed policy making (EIPM), which is participative, transparent and democratic. The two main objectives of this study were to evaluate the present state of pharmaceutical policy in Finland and discern the emphasis of pharmaceutical policy by the stakeholders' point of view in the future. The study gave the possibility to a deeper analysis of stakeholders' opinions of the Finnish pharmaceutical policy in the beginning of the year 2010 than it was possible in the official Pharmaceutical policy 2020 strategy document. Besides this, research itself was a way of practicing evidence-based policy. The SWOT-analysis were conducted among key-stakeholders as a main material of this qualitative research (n=19, response rate 59). SWOT analyses included present strengths, weaknesses, opportunities and threats regarding Finnish drug discipline of a stakeholder's point of view. Furthermore, an e-survey (n=10, response rate 31) was conducted in the end of the strategy process in order to enablegive the stakeholders to give feedback of the Pharmaceutical policy 2020 strategy process. The survey also measured that was the consensus among stakeholders reached during the strategy process. It prevailed a very good mutual understanding. Results of the research were clearly readable on the official strategy paper as well as the research could go deeper in the details of stakeholders' words than the official strategy paper. The most important emphases in the results were noticeable: condense the cooperation of stakeholders among the drug discipline to ensure efficient, good quality and patient safe pharmaceutical service and better utilizing of pharmaceutical knowledge among social and public health service. The results of this research can be utilized later as a starting point to measure how Pharmaceutical policy 2020 strategy has came true. With help of this study it's also possible to verify the strategy process and Finnish national medicine policy in the 2020 decade. In Ministry of Social Affairs and Health it is also possible to think, what kind of legislative changes it demands to implement the needed changes among the drug discipline.
  • Tavoitteena kansallinen lääkeinformaatiostrategia : lääkepoliittiset toimet kuluttajille suunnatun lääkeinformaation laadun ja saatavuuden parantamiseksi Suomessa ja Euroopan unionissa 2000-luvulla 
    Salonen, Iiro (2010)
    It was given a task to the Finnish Medicines Agency (Fimea) to prepare a national Medicines Information Strategy. The strategy process can be divided into four stages: 1) the collection and analysis of the information, 2) the determination of the strategy and the vision, 3) the realization and 4) the follow-up stage of the strategy. In the European Union (EU) the High Level Pharmaceutical Forum has drawn up the criteria for the high quality medicines information (MI) and the recommendations to improve the quality and availability of the MI directed to the consumers. The most significant medicines related political actions in Finland in the 21st century are the Medicine policy 2010 -document, the strategies of the National Agency for Medicines and the TIPPA-project. The objective of the Master's thesis was to produce the information to Fimea's MI work. The electric questionnaire was drawn up in the Ministry of Social Affairs and Health. After a pilot test, the questionnaire was sent by email to all national Medicines Authorities in EU (n=27) in November 2009. The purpose of the questionnaire was to find out 1) the significance of the medicine information in the national legislation, 2) the possible MI strategies and 3) the control mechanisms of the medicine information directed to the consumers. The medicines information strategies were found in the United Kingdom (UK), Italy and Germany. Furthermore, the strategy process was unfinished in four countries. In the strategy of the UK 25 concrete actions were presented during a three-year strategy period to improve the quality and availability of the MI and to improve the cooperation between public and private actors. The information and communication technology (ICT) was in the centre of the medicines information offered to the consumers. ICT was utilised by publishing Patient Information Leaflets in Internet and by developing medicines information web pages, digitally patient counseling services and quality certificates. The results of the survey can be utilised as a part of the Fimea's Medicines Information Strategy process. Further studies, for example an analysis of the interest groups, are needed before the preparation of the national strategy. Furthermore, experiences of the implementation of the strategy and the results reached in the UK should be clarified.

Yhteystiedot

HELSINGIN YLIOPISTO